Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22449397 | 0.89 | ALDH1A1 (0.56) | ALDH1A1PKMHPGDMAPTL3MBTL1 | |
| SCHEMBL22449395 | 0.87 | ALDH1A1 (0.53) | ALDH1A1PKMHPGDMAPTL3MBTL1 | |
| SCHEMBL26758091 | 0.84 | L3MBTL1 (0.63) | ALDH1A1HPGDMAPTL3MBTL1KMT2A | |
| SCHEMBL1864820 | 0.80 | HCAR1 (0.52) | ALDH1A1HPGDMAPTKMT2AGAA | |
| SCHEMBL17338776 | 0.80 | FGFR1 (0.55) | ALDH1A1PKMHPGDMAPTL3MBTL1 | |
| SCHEMBL15344915 | 0.78 | DRD2 (0.50) | ALDH1A1HPGDDRD2SLC6A4KMT2A | |
| SCHEMBL3354240 | 0.78 | HTR7 (0.45) | ALDH1A1PKMMAPTDRD2SLC6A4 | |
| Imidazole SCHEMBL28191367 | 0.78 | ALDH1A1 (0.43) | ALDH1A1PKMHPGDMAPTL3MBTL1 | |
| SCHEMBL7033971 | 0.77 | FGFR1 (0.52) | ALDH1A1HPGDMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3352685 | 0.77 | MAPT (0.47) | ALDH1A1MAPTACHEHIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919510-B2 | treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain; selectively inhibits neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and/or inducible nitric oxide synthase (iNOS) | NEURAXON, INC (CA) | 2011-04-05 | — | — | US | disclosed |
| US-7919510-B2 | treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain; selectively inhibits neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and/or inducible nitric oxide synthase (iNOS) | NEURAXON, INC (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-1888568-A4 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON INC (CA) | 2009-08-12 | — | — | EP | disclosed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | disclosed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | disclosed |
| EP-1888568-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | Neuraxon Inc. (CA) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | OPRM1, NOS1, OPRK1 | ALDH1A1 1605/4885PKM 2209/4885HPGD 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.